Having inked the deal with Bayer, which triggered a €5m ($6.4m) milestone payment, Algeta has extended its collaboration with Oslo’s Institute for Energy Technology (IFE).
Under the terms of the extended deal Algeta will fund the expansion of the existing Alpharadin production site at IFE to equip it to meet expected commercial demand.
"IFE has proved to be an excellent manufacture and supply partner of Alpharadin for all our clinical trials to date”, said Andrew Kay, president and CEO of Algeta.